Month: November 2014

More, and more, are the larger players, in the health care field, loosing absolute control to more nimble, and freer thinkers. And, bringing biotech into the hands of the many, versus the few. Please do scroll down to watch the… Continue Reading →

By Motley Fool Staff November 24, 2014 There are several things that have the potential to give pharmaceutical companies problems. New drugs could have trouble getting approved, competition from generics can erode profits, and research and development costs could rise.… Continue Reading →

This one has our heads shaking. Seriously, you can buy a Nobel Prize? What’s next for sale in Science? eBay here we come. As a personal aside, a great one should have shared in this prize – Rosiland Elsie Franklin.… Continue Reading →

Since the beginnings of the Human Genome Project, scientists have promised that knowledge of all of our genes would enable a deeper understanding of heritable diseases, a promise currently being fulfilled using bioinformatics approaches. Millions of dollars of research have… Continue Reading →

SOURCE: Cutting Edge Information November 19, 2014 08:42 ET 69% of Pharma Companies Look to Third Party Vendors for Big Data Collection Drug Makers Turn to Specialized Vendors and Consultants to Complete Significant Portions of Big Data Initiatives RESEARCH TRIANGLE… Continue Reading →

From: The Economist, Business: Print Edition Pharmaceutical M&A Invent it, swap it or buy it Why constant dealmaking among drugmakers is inevitable Nov 15th 2014 | From the print edition

This from the BBC Business News Service: Imagine an industry that generates higher profit margins than any other and is no stranger to multi-billion dollar fines for malpractice. Throw in widespread accusations of collusion and over-charging, and banking no doubt… Continue Reading →